Enanta Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ENTA)

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported $0.33 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.27. The biotechnology company had revenue of $44.40 million for the quarter, compared to the consensus estimate of $46.98 million. Enanta Pharmaceuticals had a net margin of 29.22% and a return on equity of 15.16%. Enanta Pharmaceuticals's revenue for the quarter was down 22.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.97 EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 25th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

4 brokerages have issued 1-year price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $57.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $101.00 in the next twelve months. This suggests a possible upside of 71.1% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

News coverage about ENTA stock has trended negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Enanta Pharmaceuticals.

Enanta Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 2,230,300 shares, an increase of 15.7% from the July 31st total of 1,928,200 shares. Based on an average daily volume of 192,500 shares, the short-interest ratio is presently 11.6 days. Approximately 14.1% of the shares of the company are sold short. View Enanta Pharmaceuticals' Current Options Chain.

Some companies that are related to Enanta Pharmaceuticals include The Medicines (MDCO), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), United Therapeutics (UTHR), Blueprint Medicines (BPMC), FibroGen (FGEN), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Allakos (ALLK), Taro Pharmaceutical Industries (TARO), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Alkermes (ALKS) and Emergent Biosolutions (EBS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), NVIDIA (NVDA), Alibaba Group (BABA), Tandem Diabetes Care (TNDM), Micron Technology (MU), Tesla (TSLA) and Netflix (NFLX).

Enanta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%), Pacer Advisors Inc. (0.03%) and Advantage Investment Management LLC (0.01%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Advantage Investment Management LLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Pacer Advisors Inc.. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $59.03.

Enanta Pharmaceuticals has a market capitalization of $1.16 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]